FDA Approval Application for Linagliptin by Teva Pharmaceuticals
Teva Pharmaceuticals has submitted an original application for Linagliptin under ANDA208433 with a standard review priority.
Asset / Drug
Drug and asset intelligence for Linagliptin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
DPP-4 Inhibitor
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.